PanGenomic Health Inc - PanGenomic Health Subsidiary Launches Vitamin D Health Assessments and Announces Corporate Appointments
PR Newswire
LONDON, United Kingdom, July 06
6 July 2023
PanGenomic Health Inc.
("PanGenomic" or the "Company")
PanGenomic Health Subsidiary Launches Vitamin D Health Assessments and Announces Corporate Appointments
Vancouver, British Columbia, Canada, July 6, 2023 - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has commenced a Vitamin D health assessment service and has also launched a corporate website at mujn.ai.
"We are very excited to introduce the MUJN biomarker assessment platform at Vancouver-based Empower Health Wellness Centre. Our first service provides Empower Health practitioners with rapid in-clinic access to patient Vitamin D assessments," said Vincent Lum, CEO of MUJN Diagnostics and Co-Founder of PanGenomic Health. "Vitamin D deficiency is a global public health problem affecting over one billion people, regardless of age, ethnicity or location. Almost 20% of Canadians have deficient levels of Vitamin D due to cloud cover, smog, sunscreens, or staying indoors.1"
Current clinical research on Vitamin D has found that:
- Vitamin D helps to absorb dietary calcium and phosphorus from the intestine for use in the body for bone strength and a large variety of your body functions.
- Vitamin D suppresses the release of parathyroid hormone, a hormone that causes bone breakdown leading to osteoporosis.
- Vitamin D supports overall brain and other organ system health by strengthening the immune system. 2
1 Nair R, Maseeh A. Vitamin D: The "sunshine" vitamin. J Pharmacol Pharmacother. 2012 Apr;3(2):118-26. doi: 10.4103/0976-500X.95506.
Health Canada. 2016. Evidence review for dietary guidance: Technical report 2015.
2 Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: a systematic review. Nutr Rev. 2018 Jan 1;76(1):60-76. doi: 10.1093/nutrit/nux034
Bhattarai HK, Shrestha S, Rokka K, Shakya R. Vitamin D, Calcium, Parathyroid Hormone, and Sex Steroids in Bone Health and Effects of Aging. J Osteoporos. 2020 Jun 17;2020:9324505. doi: 10.1155/2020/9324505.
Aranow C. Vitamin D and the immune system. J Investig Med. 2011 Aug;59(6):881-6. doi:10.2310/JIM.0b013e31821b8755.
Corporate Appointments
The Company is pleased to announce that its Chief Technology Officer, Colin Quon, has been appointed CTO of MUJN Diagnostics and will cease his role as CTO of PanGenomic Health effective immediately. Mr. Quon's focus as CTO will be on the development of the MUJN Diagnostic Support System, previously announced by the Company on March 22, 2023.
The Company is also pleased to confirm that Maryam Marissen has been appointed a Director of the Company. Ms. Marissen has been CEO of PanGenomic Health since September 2022. Prior to joining PanGenomic Health, Ms. Marissen served as Chief Executive Officer at Doseology Sciences from 2021-2022.
Maryam Marissen owns 1,000,000 stock options in the Company as at the date of this announcement.
Other Current Directorships | Former Directorships and/or partnerships (within the last five years) |
PanGenomic Technologies Corp. (a subsidiary of Pangenomic Health) | Vancouver TRU Cosmetics Ltd. |
TruMIND Wellness Inc. | Doseology Sciences Inc. |
Eternal Skin Care (USA) Inc. |
|
Except as set out above, there is no further information regarding Maryam Marissen that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.
The Directors of PanGenomic Health take responsibility for this announcement.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
About MUJNDiagnostics
MUJN Diagnostics Inc. is a wholly-owned subsidiary of PanGenomic Health Inc. and is focused on developing a decision support system for alternative healthcare providers. MUJN's Decision Support System will include biomarker diagnostics, symptom and treatment tracking, and personalized health analytics, with the goal of empowering healthcare providers and their patients towards better outcomes.
About PanGenomic Health
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalised, evidence-based information about natural treatments. The Company's initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.
The Directors of PanGenomic take responsibility for this announcement.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For more information, please contact:
Jerry Lai, Investor Relations Maryam Marissen, President & CEO
PanGenomic Health Inc. PanGenomic Health Inc.
778 743 4642 778 743 4642
ir@pangenomic.com info@pangenomic.com
Novum Securities Limited, AQSE Corporate Advisor
David Coffman / George Duxberry
Tel: +44 (0)207 399 9400
Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512
This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic and the consideration to be paid to PanGenomic. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward looking statements. Although PanGenomic believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic can give no assurance that they will prove to be correct. In particular, there is no assurance that MUJN Diagnostics and/or Psy Integrated will be able to complete trial biomarker testing program within the timeframes expected, or at all. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic's disclosure documents which can be found under PanGenomic's profile on www.sedar.com.
